Comparison of extracorporeal cellular therapy (ELAD ® ) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure

Background Preliminary evidence of safety and efficacy of an extracorporeal cellular therapy (ELAD®) has been demonstrated in subjects with acute forms of liver failure. This study compared ELAD with standard of care in Chinese subjects with acute-on-chronic liver failure (ACLF), predominantly secondary to chronic viral hepatitis.